Coenzyme q10 administration in community-acquired pneumonia in the elderly.
Coenzyme q10 administration in community-acquired pneumonia in the elderly.
复制标题
DOI：
10.5812/ircmj.18852
复制
发表时间：
2014-12
影响因子：
0.4
通讯作者：
Nayebzadeh B
中科院分区：
文献类型：
--
作者：
Farazi A;Sofian M;Jabbariasl M;Nayebzadeh B
社区获得性肺炎（CAP）通常被认为是老年人发病和死亡的主要原因。本研究旨在评估连续性辅酶Q10（CoQ 10）治疗老年CAP的疗效。住院的老年CAP患者（通过使用定义的临床和放射学标准诊断）随机接受口服辅酶Q10（200 mg/d）或安慰剂14天，沿着抗生素。测量第3、7和14天的主要和次要结局。疾病严重程度采用CURB-65指数进行评分。使用SPSS进行统计分析，P值< 0.05被认为是显著的。我们招募了150名患者参与这项研究。然后对141例患者进行分析，其中试验组70例，对照组71例。试验组和对照组的平均年龄分别为67.6 ± 7.2岁和68.7 ± 7.9岁。试验组第3天和第7天临床治愈分别为24例（34.3%）和62例（88.6%）（P值= 0.6745），安慰剂组分别为22例（31%）和52例（73.2%）（P值= 0.0209）。与安慰剂组相比，辅酶Q10组患者退热更快（P值= 0.0206），住院时间更短（P值= 0.0144）。重症肺炎患者的亚组分析显示，第14天的临床治愈率存在差异。CoQ 10组治疗失败率低于安慰剂组（10%对22.5%，P值= 0.0440）。两组不良事件发生率相似，且较少。辅酶Q10给药没有严重的副作用，可以改善住院老年CAP的预后;因此，我们建议将其作为老年患者的连续治疗。
Community-acquired pneumonia (CAP) is generally considered a major cause of morbidity and mortality in the elderly. This study aimed to assess the efficacy of adjunctive coenzyme Q10 (CoQ10) in the treatment of elderly CAP. Hospitalized elderly patients with CAP (diagnosed by using defined clinical and radiological criteria) were randomized to receive oral CoQ10 (200 mg/d) or placebo for 14 days, along with antibiotics. Primary and secondary outcomes on days 3, 7, and 14 were measured. Disease severity was scored using CURB-65 index. Statistical analysis was performed using SPSS and P value < 0.05 was considered significant. We enrolled 150 patients for this research. Then, 141 patients, including 70 patients in the trial group and 71 patients in the control group were analyzed. Mean age of the trial and control groups were 67.6 ± 7.2 years and 68.7 ± 7.9 years, respectively. Clinical cure at days 3 and 7 were 24 (34.3%) and 62 (88.6%) in the trial group (P value = 0.6745) and 22 (31%) and 52 (73.2%) in the placebo group (P value = 0.0209). Patients on CoQ10 had faster defervescence (P value = 0.0206) and shorter hospital stay (P value = 0.0144) compared with the placebo group. The subgroup analysis of the patients with severe pneumonia showed differences in clinical cure at day 14. Treatment failure was less in CoQ10 group than in the placebo group (10% versus 22.5% and P value = 0.0440). Adverse events in two groups were few and similar. CoQ10 administration has no serious side effects and can improve outcome in hospitalized elderly CAP; therefore, we recommend it as an adjunctive treatment in elderly patients.
登录
查看更多内容
影响因子：
11.8
作者：
Menéndez, R;Torres, A;Molinos, L
通讯作者：
Molinos, L
影响因子：
120.7
作者：
Halm, EA;Fine, MJ;Singer, DE
通讯作者：
Singer, DE
影响因子：
6
作者：
Quinzii, C. M.;Lopez, L. C.;Hirano, M.
通讯作者：
Hirano, M.
影响因子：
14.5
作者：
Bogdanov, Mikhail;Matson, Wayne R.;Beal, M. Flint
通讯作者：
Beal, M. Flint
影响因子：
120.7
作者：
Fry, AM;Shay, DK;Anderson, LJ
通讯作者：
Anderson, LJ